"Pharmacovigilance and its Role in Combating Covid-19 Pandemic"

Introduction: Corona viruses are a group of viruses belonging to the family of Coronaviridae, which infect both animals and humans. Human corona viruses can cause mild disease similar to a common cold, while others cause more severe disease (such as MERS - Middle East Respiratory Syndrome and SARS – Severe Acute Respiratory Syndrome). A new corona virus that previously has not been identified in humans emerged in Wuhan, China in December 2019. Whereas access to treatment is a major priority in any emergency health situation such as the COVID-19 pandemic, patient safety must not be compromised by the need for access. Access to the wrong, poor quality or unsafe product might have worse consequences than lack of access. The global pandemic have seen reports of increased sales and perhaps hoarding of some medical products, such as chloroquine, hydroxy chloroquine, and lopinavir/ritonavir, in some countries, as well as increased sales of fake medical products and medicines related to COVID-19, such as hand sanitizers, and antiviral medications. The COVID-19 pandemic has made patient safety headlines as the world looks to existing therapies and new innovations to treat those affected and help prevent future infections. The current challenges posed by the COVID-19 pandemic have also prompted regulatory agencies to reconsider their requirements and have emphasized the importance of electronic reporting to ensure data exchange for patient safety.

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)